Asset
ENTINOSTAT
Syndax Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00754312 | phase1 | terminated | 2008-06-01 | 2009-02-28 | Syndax Pharmaceuticals | A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer |
FDA applications (0)
This company has no applications containing this asset.